阶段(地层学)
化疗
危险系数
外科
癌症
不良事件通用术语标准
泌尿科
前瞻性队列研究
作者
Ana Maria Dias Fachini,Antonio Carlos Zuliani,Luis Otávio Sarian,Julio Cesar Teixeira,Sérgio Carlos Barros Esteves,Helymar da Costa Machado,Luiz Carlos Zeferino
标识
DOI:10.1016/j.ygyno.2020.11.029
摘要
Abstract Objective The present analysis determined the disease free survival (DFS) and overall survival (OS) at up to 14 years of follow-up in women who participated in our previous phase 3 randomized controlled clinical trial, in which women with stage IIIB squamous cervical cancer received either cisplatin plus RT or RT alone for treatment. The first study showed that the addition of cisplatin to RT offered a significant benefit in DFS, but not in OS. Methods The present analysis examined DFS and OS in 146 women from the original cohort (72 patients in the CRT arm and 74 patients in the RT-only arm) with follow-up of up to 14 years. Results Longer term follow-up showed that treatment with CRT offers a significant benefit in DFS and OS compared with treatment with RT only. Patients who received RT alone had significantly worse OS (HR, 1.88; 95% CI, 1.09–3.24) and DFS (HR, 1.82; 95% CI, 1.07–3.08) compared with patients who received CRT. The multivariate analyses also showed that the patients with baseline Karnofsky performance status (KPS) Conclusions For stage IIIB cervical cancer, treatment with CRT offers a significant benefit in DFS and OS compared with treatment with RT only.
科研通智能强力驱动
Strongly Powered by AbleSci AI